今年是武田制药进入中国30周年。“武田将继续深耕上海，并进一步加大投资,积极利用上海雄厚的人才资源和规范开放的经营环境。”武田制药全球高级副总裁、武田中国总裁单国洪认为，驻华跨国药企可以成为一个开放包容的交流桥梁，促进上海本地企业和重要外资企业进行交流合作，分享并汲取更多经验和资源，可以稳步开展各项跨国产业合作项目。

This year marks the 30th anniversary of Takeda Pharmaceutical's entry into China. "Takeda will continue to cultivate in Shanghai, further increase investment, and actively utilize Shanghai's abundant human resources and well-ordered and open business environment." Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical and President of Takeda China, believes that multinational pharmaceutical companies in China can become an open and inclusive communication bridge, promote exchanges and cooperation between local enterprises in Shanghai and important foreign-funded enterprises, share and learn more experience and resources, and can steadily carry out various transnational industrial cooperation projects.

03

建议未来持续推动统筹调度机制

Continue to promote the overall scheduling mechanism

上海市商务委制定了全市统筹推进外商投资促进工作实施方案，并希望与重要外资企业建立“投资上海”网络。单国洪认为，这是一项十分利好外企的政策，体现了上海市政府对优化营商环境、促进外资发展的高度重视。该机制的建立将有利于进一步提升外商投资便利化水平，为外企提供更加高效、便捷的服务，从而吸引更多外资落户上海。”

The Shanghai Municipal Commission of Commerce has formulated an implementation plan for the city's overall promotion of foreign investment, and hopes to propose an "investment in Shanghai" network with important foreign-funded enterprises. Shan Guohong believes that this is a very favorable policy for foreign companies, reflecting the great importance the Shanghai Municipal People's Government attaches to optimizing the business environment and promoting the development of foreign investment. The establishment of this mechanism will help further improve the level of foreign investment facilitation, provide more efficient and convenient services for foreign enterprises, and thus attract more foreign capital to settle in Shanghai."

上海进一步推动基因治疗科技创新和产业高质量发展，加快打造生物医药产业高地，持续深化与落实相关产业促进精神。单国洪建议，上海以基因治疗的准入支付创新为抓手，从三方面出发：一是上海未来可以持续推动统筹调度机制，建立服务专班，健全统筹协调机制，明确各部门职责分工，压实工作责任。二是为确保机制高效运转，定期召开统筹调度会议，明确问题受理、流转、办理、反馈等环节和时限，确保问题及时高效解决。三是用好用足浦东新区法规立法权，探索基因治疗的准入支付创新，争取先行先试、取得突破。

Shanghai further promotes gene therapy technology innovation and high-quality industrial development, accelerates the creation of a highland for the biomedical industry, and continues to deepen and implement the spirit of promoting related industries. Shan Guohong suggested that Shanghai should focus on the innovation of access and payment for gene therapy, starting from three aspects: First, Shanghai can continue to promote the overall planning mechanism in the future, establish special service departments, improve the overall planning and coordination mechanism, and clarify the division of responsibilities of various departments to implement work responsibilities. Second, in order to ensure the efficient operation of the mechanism, regular overall planning and scheduling meetings should be held to clarify the links and time limits of problem acceptance, transmission, handling, and feedback, so as to ensure that problems are resolved in a timely and efficient manner. Third, Shanghai should make good use of the legislative power of Pudong New Area, explore the access and payment innovation of gene therapy, and strive to try first and make breakthroughs.

04

致力与中国合作伙伴共同构建创新生态圈

Committed to building an innovation ecosystem with our partners

“对外合作”一直是武田制药的核心研发战略之一。在全球范围内，武田制药积极寻求与社会各界合作，通过多元化的合作模式来加强创新。目前，武田制药有超过200多个的战略合作伙伴;这样的合作也为武田制药的研发带来了许多成果和机遇。

"Foreign cooperation" has always been one of the core R&D strategies of Takeda Pharmaceutical. Globally, Takeda Pharmaceutical actively seeks cooperation with all sectors of society to strengthen innovation through diversified cooperation models. At present, Takeda Pharmaceutical has more than 200 strategic partners, and the cooperation brought by these partners has also brought many achievements and opportunities to the research and development of Takeda Pharmaceutical.

在中国，武田制药致力于与中国合作伙伴共同构建创新生态圈，不断扩大与本土企业的合作范围。这些合作对中国创新加速融入全球创新体系，并成为全球重要的医药创新源头之一将会起到重要的推动作用。

In China, Takeda Pharmaceutical is committed to building an innovation ecosystem with Chinese partners and continuously expanding the scope of cooperation with local companies. These collaborations will play an important role in promoting the integration of Chinese innovation into the global innovation system and becoming one of the important sources of pharmaceutical innovation in the world.

无论是帮助上海企业走出去，还是帮助吸引更多企业投资落户上海，单国洪认为,驻华跨国药企可以成为一个开放包容的交流桥梁，促进上海本地企业和重要外资企业进行交流合作，分享并汲取更多经验和资源，“我们可以稳步开展各项跨国产业合作项目，促进中国的技术创新和中外人才交流，进一步提升上海的产业竞争力和吸引力。同时，通过这个跨国桥梁，上海的企业可以积极地走出去，去世界舞台展示自己的风采，让世界更多地认识我们，认可我们。”

Whether it is helping Shanghai enterprises to go global or helping attract more enterprises to invest and settle in Shanghai, Shan Guohong believes that multinational pharmaceutical enterprises in China can become an open and inclusive communication bridge, promote exchanges and cooperation between local enterprises in Shanghai and important foreign-funded enterprises, share and learn more experience and resources, "We can steadily carry out various transnational industrial cooperation projects, promote China's technological innovation and the exchange of Chinese and foreign talents, and further enhance Shanghai's industrial competitiveness and attractiveness. At the same time, through this transnational bridge, Shanghai enterprises can actively go out, show their demeanor on the world stage, and let the world know more about us and recognize us.

武田制药希望与更多国内及上海的本土合作伙伴深入交流，多元化嫁接市场资源，落地创新成果，助力中国创新药乘风出海，为上海乃至中国医药事业的高质量发展贡献力量。

Takeda Pharmaceutical hopes to have in-depth exchanges with more local partners in China and Shanghai, diversify market resources, implement innovative achievements , help Chinese innovative drugs take advantage of the development trends and go overseas, and contribute to the high-quality development of Shanghai and even China's pharmaceutical industry.

（完）

来源：“投资上海”杂志